An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(12 sites)

United States

UCLA Medical Center, Los Angeles, California

Lucile Packard Children's Hospital at Stanford, Palo Alto, California

Altman Clinical and Translational Research Institution, San Diego, California

Canada

Stollery Children's Hospital University of Alberta, Edmonton, Alberta

Hospital For Sick Children, Toronto, Ontario

France

Hôpital Necker - Enfants Malades APHP, Paris

Netherlands

Erasmus MC, Rotterdam

Universitair Medisch Centrum Utrecht, Utrecht

Spain

Hospital Universitario Cruces, Barakaldo, Vizcaya

Hospital Universitario 12 de Octubre, Madrid

United Kingdom

Birmingham Children's Hospital NHS Foundation Trust, Birmingham

Royal Manchester Childrens Hospital, Manchester